, entitled: "Simple Purification Method for Anti-Glycolipid Anti body. Using Polystyrene Latex Beads Coated with Gan gliotetraosylceramide'. Holmgren, et al., Eur, J. Biochen, 106:371-379 (1980) , entitled: "Polystyrene-Adsorbed gangliosides for In vestigation of the Structure of the Tetanus-Toxin Re ceptor". Willoughby et al., Pediactric Research, vol. 25, No. 4, Part 2, (1989) 79, pp. 148-154, 1987 .
Despite the important advances of biomedical re search in the last decades that have led to the develop ment of sophisticated therapeutic techniques, diarrheal diseases continue to be a major cause of mortality among infants and young children in the developing world. Thus there is a need in the art for methods and products for treating enteric viral diseases leading to diarrhea in children.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a method of treating a human or other mammal to prevent or dimin ish viral infections.
It is another object of the invention to provide a composition for preventing enteric viral infections in infants.
It is yet another object of the invention to provide a composition for treating children and adults infected with enteric viruses.
It is still another object of the invention to provide a composition for preventing and treating enteric viral infections. These and other objects of the invention are provided by one or more of the embodiments described below.
In one embodiment of the present invention a method is provided of treating a human or other mammal to prevent or diminish enteric viral infections, comprising: orally administering an effective amount of gangliotet raosylceramide to a human or other mammal to bind enteric viruses.
In another embodiment of the invention a composi tion is provided comprising an infant nutrient formula and an effective amount of gangliotetraosylceramide for binding to enteric viruses.
In still another embodiment of the invention a com position is provided comprising: a rehydration formula and an effective amount of gangliotetraosylceramide for binding to enteric viruses.
In yet another embodiment of the present invention a composition is provided, comprising: gangliotetraosylc eramide bound to a non-absorbable support.
The present invention provides the art with a prophy lactic and therapeutic means for readily treating diar 
DETALED DESCRIPTION
It is a discovery of the present inventors that a broad range of enteric viruses which are pathogenic to hu mans and other mammals are bound by a single glyco lipid molecule, namely gangliotetraosylceramide (GA1). This is surprising in view of the fact that these viruses are known to bind to different cellular recep tors. This is also surprising because gangliotetraosylcer amide is a neutral glycolipid, whereas some Reoviridae have already been shown to bind to acidic glycopro teins. The glycolipid of the present invention, also known as asialo-GM1 as well as GA1, can be used to treat humans both preventively, i.e., as a prophylactic, as well as therapeutically, i.e., after infection to diminish the severity of infection. While human enteric viruses have been found to bind to GA1, other viruses may also employ GA1 as a common binding mechanism to cells. For example, animal viruses may bind to GA1, as there is evidence that GA1 exists in mouse enterocytes. In addition, other viruses of humans may bind to GA1, for example, respiratory viruses, such as adenovirus, influ enza, parainfluenza, and respiratory syncytial virus.
According to the method of the present invention the gangliotetraosylceramide is orally administered. The GA1 glycolipid may be obtained commercially, for example from the Sigma Chemical Co., St. Louis, Mo. GA1 can also be prepared by acid hydrolysis of GM1 glycolipid as described in Dahms, et al., J. Neurosci ence, vol. 3, pp. 806-817, 1983 . As this neutral glyco lipid is acid-stable, it does not need to be protected to survive in the gastrointestinal tract. However, it may be desirable to bind the neutral glycolipid to a non-absorb able support. The selection of a support is within the skill of the art and such supports include beads, resins, natural or synthetic polymers. One particularly pre ferred non-absorbable support is cholestyramine, which has previously been shown to be effective as an antidiar rheal agent for bacterial pathogens. The neutral glyco lipid may be bound to the non-absorbable support via a simple absorption or via a covalent linkage. Methods for performing both such types of binding are well 5, 192, 551 3 known in the art. (See, e.g., Tiemeyer, et al., J. Biol. Chem, vol. 264, pp. 1671 -1681 , 1989 , and Taki, et al., J. Biochem. vol. 91, pp. 1813 -1816 , 1982 If absorption is to be used as the means of attachment, a hydrophobic bead is preferred.
Other means of administering the neutral glycolipid of the present invention involve forming small lipid particles comprising the gangliotetraosylceramide. Such lipid particles may be, for example, vesicles, mi celles, or liposomes. In addition, the gangliotetraosylc eramide may be administered in the form of a capsule or tablet. Suitable formulations can be prepared according to methods well known in the art. See, e.g., Rennington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., latest edition. Although applicants do not wish to be bound by any particular theory, it is thought that bound or particulate forms of the neutral glycolipid may be desirable in order to keep a high local density of the glycolipid.
As a treatment for diarrhea, the neutral glycolipid of the present invention has benefits over traditional anti biotic therapy. Antibiotics have the undesirable charac teristic of being effective against normal gastrointestinal bacterial colonizers. Thus antibiotic therapy often leads to infection by secondary infectious agents because the antibiotic has eliminated the normal competitors for the particular ecological niche.
Rehydration formulae are often administered to re plenish electrolytes which are lost due to severe diar rhea. In some cases they are administered intrave nously, and in other cases oral administration is success ful. In one embodiment of the present invention it is contemplated that at effective amount of the gangliotet raosylceramide will be admixed with a rehydration formula for administration to a patient suffering from diarrhea. Sufficient gangliotetraosylceramide should be administered to bind to a substantial portion of the en teric viruses causing the infection so that the infection is diminished. Rehydration formulae are well known in the art and are commercially available.
In another embodiment of the present invention it is contemplated that the gangliotetraosylceramide of the present invention will be administered in an infant nutri ent formula. Once again, an effective amount of the gangliotetraosylceramide must be used to bind to en teric viruses in the gastrointestinal tract. Infant nutrient formulae are well known in the art and are commer cially available. The infant nutrient formula containing the neutral glycolipid of the present invention may be given to children routinely in areas where diarrhea is endemic. Alternatively, when a viral diarrhea outbreak is occurring, for example in a hospital, infants can be given the nutrient formula of the present invention in order to prevent spread of the infection to uninfected infants as well as to treat infected infants.
An effective amount of gangliotetraosylceramide according to the present invention is one that is effec tive to bind to the targeted viruses. Generally, for oral administration, this will be between about 10 uM and about 1 mM. Preferably, between about 12 ug and 1.2 ng will be administered to a child and between about 200 ug and 10 mg will be administered to an adult.
In the case of treatment for respiratory viruses, a The following experimental data are presented to exemplify the invention. The invention is however not limited to these examples but is defined by the foregoing description and the claims which follow.
EXAMPLE
This example demonstrates that rotavirus SA11 binds with high specificity to glycolipid GA1.
Virus SA11 was grown in MA 104 cells, which are from a rhesus monkey kidney-derived cell line (avail able from MA Bioproducts, Walkersville, Md.) using previously described methods. (Hoshino, et al., Infect. Immun. 41:169-173, 1983.) Various amounts of glycolipids were spotted on high performance thin layer chromatography plates (glass backed silica gel plates, 0.2 mm thick, available from Merck, Darmstadt, Germany). The plates were devel oped in chloroform-methanol-0.25% KCl (60:35:8) . After plasticizing with polyisobutyl-methacrylate and blocking with polyvinylpyrrollidone, (available from Sigma Chemical Co., St. Louis, Mo.) as described in Magnani, et al., (Methods in Enzymology, vol. 83, pp. 235-240, 1982 ) the glycolipids were probed with la beled virus SA11.
Two methods of labeling the virus were used, meta bolic labeling with 3S-methionine and oxidative label ing with 125I-iodine. All viruses were purified on iso pycnic cesium chloride gradients or on metrizamide gradients.
Rotavirus SA11 bound to: GA1 at concentrations as low as 30 pmol; to neolactotetraosylcermide (nLC4) at concentrations of 500 pmol and above; and to other glycolipids (Gba, GA2, Lac, GD1a, GM, GM3) only at concentrations greater than 1000 pmol. GA1 and nLC4 differ only in the substitution of an N-acetyl-glucosa mine moiety for an N-acetyl-galactosamine moiety.
Lace Gal(beta)1 -4 Gic (beta)1 -Cer; GD=NeuAc(alpha)2 -3 Gal(beta)1 -3 Gat -NAc(beta)1 -40NeuAc (alpha)2-3) Gal(beta) -4Glc(beta)1 -1Cer; GMl=gal(beta)1 -3 GalNAc(beta)1 -4 (NeuAc (alpha)2-3) Gal(beta)1 -4 Gilcobeta)l-Cer; GM3-Neuacalpha)2 -3 Gal(beta)1 -4 Glic(beta)1 -1 Cer; GA2=GalNAccbeta)1 -4 Gal(beta)1 -4 Gic(beta) -1 Cer; GA2s GalNAc(betal -4 Gal(beta)1 -4 Glcobeta)1 -1 Cer; GAi=Gal(beta)1 -3 Gal Nac(beta)1 -4 Gal(beta)1 -4 Glcobeta)1 -Cer; Gbs GalNAcbeta) -4 gal(beta)1 -4 Gal(beta)l -4 GilcCbeta)1 -1 Cer; n.Lc4s 4 Gal(beta)1 -4 GlcNAc(beta) -4 Gal(beta) -4 Gicbeta) -1 Cer.
EXAMPLE 2 This example demonstrates that the binding of SA11 rotavirus is exquisitely specific for the GA1 molecule. Enzymatic oxidation of the terminal galactose abolishes virus binding. w GA1 glycolipid was treated with the enzyme galac tose oxidase (1 unit) as well as 4 units of horseradish peroxidase and 20 units of catalase in 50% tetrahydrafu ran overnight at room temperature, and the products were chromatographically separated as described in Example 1. The chromatogram was visualized using char (10% H2SO4 and 50% EtOH in water and baked at 120 C, for 10-5 min.
As shown in FIG. 1b , most of the GA1 was con verted to the oxidized (aldehyde) form which is faster migrating than genuine GA1. When the chromatogram was probed with radiolabeled SA1 rotavirus, only gen uine GA1 bound virus; the oxidized form bound no detectable SA11 virus. (See FIG. 1(a) . 'GA1 indicates the migration position of the oxidized form of GA1. 5,192,551 5 This experiment shows the specificity of binding of the SA11 virus to the GA1 glycolipid. Chemical oxidative treatment of GA1 with periodate also abolishes SA11 virus binding. EXAMPLE 3 This example demonstrates that the SA11 virus bind ing to GA1 is mediated through an interaction with viral protein VP7.
Glycolipids were separated on a chromatogram, as described in Example 1, and probed with radiolabeled SAll virus. Two regions of binding were scraped from the plate, one corresponding to the migration of GA1 and the other corresponding to large amounts of nonpo lar lipids. These two regions are labeled B and A, re spectively, in FIG. 2(a) . The proteins in the scrapings were solubilized in Laemmlisample buffer and run on 10% polyacrylamide gels. ( See FIG. 2(b) ). Lane (a) which contains protein scraped from region. A shows that many different viral proteins bound to the glyco lipid spot containing nonpolar lipids, whereas the GA1 glycolipid bound predominantly protein VP7 (Lane (b)). Lane (c) shows the migration of labeled viral pro teins which had not been pre-bound to the chromato gram.
Binding of SAll rotavirus to GA1 can be blocked by neutralizing antibodies (directed against VP7). How ever, antibodies raised against VP7 of other serotypes do not block SA11 binding to GA1. EXAMPLE 4 This example demonstrates that all non-enveloped enteric viruses tested exhibit binding to GA1 glycolipid. The ability to bind to GA1 was assessed by binding the radiolabeled viruses to glycolipids resolved on thin layer chromatography plates by the method of Mag nani, supra. All viruses tested bound to GA1. Bovine serum albumin, labeled with 125I did not bind to GA1.
Poliovirus 1 bound to GA1 when it was labeled with 3S-methionine, but not when labeled with 125I. This is consistent with references in the literature reporting that the harsh conditions employed to radioiodinate proteins destroy poliovirus infectivity. EXAMPLE 5 This example demonstrates that GA1 bound to poly styrene beads is able to reduce-viral infectivity. GA1 (asialo GM1) and GM1 were bound to polysty rene beads by the method of Taki, et al. (J. Biochem, vol. 91, pp. 1813 -1816 , 1982 . Briefly, the glycolipids are dispersed in water and the dispersion is heated to 80' C. just long enough so that the lipids go into solution. The polystyrene beads are then mixed into the solution and the glycolipids adsorb onto the beads.
The glycolipid-coated beads were then mixed with crude SA11 viral lysates and incubated at 37' C. for 60 min. The beads were removed by centrifugation and the supernatant was used to infect Malo4 cells.
The difference in numbers of plaques formed in the control infections (virus alone) and in the infections with GM1-bead treated and GA1-bead treated lysates are shown in FIG. 3 . On a per lipid basis, GA1 inhibited viral infections 50-fold greater than GM1. GA1 inhibi tion of viral infections was essentially complete.
When a different method (Roseman, et al., unpub lished, adapted from Schnaar) was used to bind glyco lipids to the polystyrene beads the absolute magnitude of the inhibition was greatly reduced. This method involves the dissolving of GA1 in 50% ethanol fol lowed by the evaporation of the aqueous component. Although the relative inhibition of GA1 was still much greater than GM1, globoside, GM3, and GD1a. Al though the inventors do not wish to be bound by any particular theory, it is believed that the difference is due to the greater number of glycolipids which bind to the beads by the Taki method leading to a higher density of glycolipids per bead. 4. The method of claim 3 wherein the enteric viruses are selected from the group consisting of rotaviruses, reoviruses, polioviruses, and coxsackie viruses.
5. The method of claim 1 wherein the gangliotet raosylceramide is bound to an enterically non-absorba ble support.
6. The method of claim 5 wherein the non-absorbable support is a hydrophobic bead.
7. The method of claim 5 wherein the gangliotet raosylceramide is bound to the enterically non-absorba ble support by adsorption.
8. The method of claim 5 wherein the gangliotet raosylceramide is bound by a covalent linkage.
